2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1410

Is the Self-Assessment of Disease Activity (auto-DAS28) By Patients a Feasible and Acceptable Measure over the Long Term in Rheumatoid Arthritis (RA)? Three-Year Follow-up of a Nurse-Led Program in 771 Patients with Established RA

Quality Measures and Quality of Care - Poster II

9:00AM-11:00AM: Abstract Number: 1689

Ixekizumab Provides Improvements through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1688

Ixekizumab Provides Sustained Improvement up to 52 Weeks of Disease Activity As Assessed By Composite Measure Scores in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1678

JAK STAT Kinase Cascade Regulates the IL-23/IL-17 Cytokine Axis in Psoriatic Arthritis

Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster I

9:00AM-11:00AM: Abstract Number: 1435

KCa1.1 Potassium Channels Are a Novel Therapeutic Target on Fibroblast-like Synoviocytes in Rheumatoid Arthritis

Rheumatoid Arthritis – Animal Models - Poster II

9:00AM-11:00AM: Abstract Number: 1853

Klf5+/-;Fli1+/- Mice Recapitulate Protracted Wound Healing and Cardiac and Intestinal Involvement Associated with Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics - Poster II

9:00AM-11:00AM: Abstract Number: 1254

Knee Pain and Patient Preference for Knee Replacement: Healthcare Access Matters

Healthcare Disparities in Rheumatology - Poster II

9:00AM-11:00AM: Abstract Number: 1952

Kv1.3 Channel Blockade Modulates the Effector Function of B Cells in Granulomatosis with Polyangiitis

Vasculitis - Poster II: ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1183

Lack of Awareness of Sexual Health in Rheumatology. High Prevalence of Sexual Dysfunction Among Women with Rheumatic Diseases

Epidemiology and Public Health - Poster II

9:00AM-11:00AM: Abstract Number: 1608

Lack of Early Change in Disease Activity Score Predicts the Likelihood of Achieving Low Disease Activity at Month 6: Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naive Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1698

Late Onset Psoriatic Arthritis in a Longitudinal Cohort: Disease Presentation, Activity over Time and Prognosis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1618

Leflunomide, Sulfasalazine and Hydroxychloroquine for Rheumatoid Arthritis: Efficacious but Poorly Tolerated

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1113

Leptin Promotes Distribution of Mast Cells in Salivary Glands of Patients with Primary Sjogren’s Syndrome

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster I

9:00AM-11:00AM: Abstract Number: 1495

Lipoprotein(a) Concentrations in Rheumatoid Arthritis on Biologic Therapy: Results from the Cardiovascular in Rheumatology [CARMA] Study Project

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1713

Long-Term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].